46. Malignant rheumatoid arthritis Clinical trials / Disease details
Clinical trials : 4,325 / Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03511625 (ClinicalTrials.gov) | October 2, 2018 | 10/4/2018 | The Effects of Acthar on Synovial Inflammation in Rheumatoid Arthritis | The Effects of Acthar on Synovial Inflammation in Rheumatoid Arthritis: A Pilot Study | Rheumatoid Arthritis | Drug: Acthar Injectable Product;Drug: Depo medrol | Attune Health Research, Inc. | Mallinckrodt | Active, not recruiting | 18 Years | N/A | All | 6 | Phase 3 | United States |
| 2 | NCT02541955 (ClinicalTrials.gov) | July 20, 2017 | 1/9/2015 | Use of Acthar in Rheumatoid Arthritis (RA) Related Flares | Use of Acthar in Rheumatoid Arthritis Related Flares | Rheumatoid Arthritis (RA) | Drug: Acthar | Veena Ranganath, MD, MS | NULL | Recruiting | 18 Years | N/A | All | 40 | Phase 4 | United States |
| 3 | NCT03082573 (ClinicalTrials.gov) | March 3, 2017 | 13/3/2017 | Efficacy, Radiographic and Laboratory Changes in Refractory Rheumatoid Arthritis Patients Treated With H.P. Acthar Gel | Open-label, Pilot Protocol of Patients With Rheumatoid Arthritis Who Were Treated With H.P. Acthar Gel After an Incomplete Response to Combinations of DMARDs and Biologic DMRADs | Rheumatoid Arthritis | Drug: H.P. Acthar gel | Iraj Sabahi Research Inc. | Mallinckrodt | Recruiting | 21 Years | N/A | All | 30 | Phase 4 | United States |
| 4 | NCT02919761 (ClinicalTrials.gov) | November 7, 2016 | 26/9/2016 | Safety and Effectiveness of Acthar Gel in Participants With Rheumatoid Arthritis | A Multicenter, 2 Part Study to Assess the Efficacy and Safety of Acthar Gel in Subjects With Rheumatoid Arthritis With Persistently Active Disease Despite Dual-DMARD Treatment | Arthritis, Rheumatoid | Drug: Acthar Gel;Drug: Placebo | Mallinckrodt | NULL | Completed | 18 Years | N/A | All | 259 | Phase 4 | United States;Argentina;Mexico;Peru;Puerto Rico;Colombia |
| 5 | NCT02030028 (ClinicalTrials.gov) | November 2014 | 6/1/2014 | ACTH Gel Therapy in Rheumatoid Arthritis | Open Label Study to Evaluate Efficacy and Safety of Short-Term, Adjunctive Adrenocorticotropic Hormone (ACTH) Gel in Rheumatoid Arthritis | Rheumatoid Arthritis | Drug: ACTHAR gel | Dana Ascherman | Mallinckrodt | Recruiting | 18 Years | 100 Years | All | 20 | N/A | United States |
| 6 | NCT01984268 (ClinicalTrials.gov) | June 2014 | 8/11/2013 | ACTHAR for Acute Treatment of Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate | Adenocorticotrophic Hormone for Acute Treatment of Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate | Rheumatoid Arthritis | Drug: ACTHAR | Dartmouth-Hitchcock Medical Center | Mallinckrodt | Recruiting | 18 Years | 70 Years | Both | 60 | Phase 2 | United States |
| 7 | NCT02434757 (ClinicalTrials.gov) | February 2014 | 30/4/2015 | Addition of H.P. Acthar Gel to Treatment Regimen of Patients With Rheumatoid Arthritis | Addition of H. P Acthar Gel to Treatment Regimen of Patients With Rheumatoid Arthritis Inadequately Controlled With Biologic Disease-Modifying Antirheumatic Drugs | Rheumatoid Arthritis | Drug: H.P. Acthar Gel | Ronald J. Rapoport, MD | Questcor Pharmaceuticals, Inc. | Recruiting | 18 Years | N/A | Both | 10 | N/A | United States |